Krystal Biotech Inc
(NAS:KRYS)
$
195.64
-3.15 (-1.58%)
Market Cap: 5.62 Bil
Enterprise Value: 5.16 Bil
PE Ratio: 54.31
PB Ratio: 6.80
GF Score: 40/100 Krystal Biotech Inc at Guggenheim Genomic Medicines and Rare Disease Day (Virtual) Transcript
Mar 31, 2022 / 06:00PM GMT
Release Date Price:
$66.54
(-0.54%)
Debjit Chattopadhyay
Guggenheim Securities, LLC - Analyst
So good afternoon and thank you for joining Guggenheim's Genomic Medicine and Rare Disease Conference, day one. I am Debjit Chattopadhyay, one of the analysts representing Guggenheim therapeutics team. My privilege to host Krystal's Chairman and CEO, Krish Krishnan.
Thank you very much for your time, Krish, and really appreciate this.
Krish Krishnan
Krystal Biotech, Inc. - Chairman & CEO
No, thanks for having me.
Questions & Answers
Debjit Chattopadhyay
Guggenheim Securities, LLC - Analyst
So let's get started. But first of all, obviously, congrats on your Phase 3 win with B-VEC, much-needed option for patients and families with DEB, in general. So do walk us through sort of the level of engagement that you've had with the FDA during the conduct or the inception of the clinical trial to the change of statistical analysis plan.
Krish Krishnan
Krystal Biotech, Inc. - Chairman & CEO
No
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot